Identification of novel small molecule inhibitors of amyloid precursor protein synthesis as a route to lower Alzheimer's disease amyloid-β peptide

Tada Utsuki, Qian Sheng Yu, Diane Davidson, Demao Chen, Harold W. Holloway, Arnold Brossi, Kumar Sambamurti, Debomoy Lahiri, Nigel H. Greig, Tony Giordano

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

A wealth of independent research with transgenic mice, antibodies, and vaccines has pointed to a causative role of the amyloid-β peptide (Aβ) in Alzheimer's disease (AD). Based on these and earlier associative studies, Aβ represents a promising target for development of therapeutics focused on AD disease progression. Interestingly, a cholinesterase inhibitor currently in clinical trials, phenserine, has been shown to inhibit production of both amyloid precursor protein (APP) and Aβ. We have shown that this inhibition occurs at the post-transcriptional level with a specific blocking of the synthesis of APP relative to total protein synthesis (Shaw et al., 2001). However, the dose of phenserine necessary to block APP production is far higher than that needed to elicit its anticholinesterase activity, and it is these latter actions that are dose limiting in vivo. The focus of this study was to screen 144 analogs of phenserine to identify additional small molecules that inhibit APP protein synthesis, and thereby Aβ production, without possessing potent acetylcholinesterase (AChE) inhibitory activity. An enzyme-linked immunosorbent assay was used to identify analogs capable of suppressing APP production following treatment of human neuroblastoma cells with 20 μM of compound. Eight analogs were capable of dose dependently reducing APP and Aβ production without causing cell toxicity in further studies. Several of these analogs had little to no AChE activities. Translation of APP and Aβ actions to mice was demonstrated with one agent. They thus represent interesting lead molecules for assessment in animal models, to define their tolerance and utility as potential AD therapeutics.

Original languageEnglish
Pages (from-to)855-862
Number of pages8
JournalJournal of Pharmacology and Experimental Therapeutics
Volume318
Issue number2
DOIs
StatePublished - 2006

Fingerprint

Amyloid beta-Protein Precursor
Serum Amyloid A Protein
Amyloid
Alzheimer Disease
Peptides
Cholinesterase Inhibitors
Acetylcholinesterase
Neuroblastoma
Transgenic Mice
Disease Progression
Proteins
Therapeutics
Vaccines
Animal Models
Enzyme-Linked Immunosorbent Assay
Clinical Trials
Antibodies
Research
phenserine

ASJC Scopus subject areas

  • Pharmacology

Cite this

Identification of novel small molecule inhibitors of amyloid precursor protein synthesis as a route to lower Alzheimer's disease amyloid-β peptide. / Utsuki, Tada; Yu, Qian Sheng; Davidson, Diane; Chen, Demao; Holloway, Harold W.; Brossi, Arnold; Sambamurti, Kumar; Lahiri, Debomoy; Greig, Nigel H.; Giordano, Tony.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 318, No. 2, 2006, p. 855-862.

Research output: Contribution to journalArticle

Utsuki, Tada ; Yu, Qian Sheng ; Davidson, Diane ; Chen, Demao ; Holloway, Harold W. ; Brossi, Arnold ; Sambamurti, Kumar ; Lahiri, Debomoy ; Greig, Nigel H. ; Giordano, Tony. / Identification of novel small molecule inhibitors of amyloid precursor protein synthesis as a route to lower Alzheimer's disease amyloid-β peptide. In: Journal of Pharmacology and Experimental Therapeutics. 2006 ; Vol. 318, No. 2. pp. 855-862.
@article{36bcec75f2ed4ff981bd0d81b23222fd,
title = "Identification of novel small molecule inhibitors of amyloid precursor protein synthesis as a route to lower Alzheimer's disease amyloid-β peptide",
abstract = "A wealth of independent research with transgenic mice, antibodies, and vaccines has pointed to a causative role of the amyloid-β peptide (Aβ) in Alzheimer's disease (AD). Based on these and earlier associative studies, Aβ represents a promising target for development of therapeutics focused on AD disease progression. Interestingly, a cholinesterase inhibitor currently in clinical trials, phenserine, has been shown to inhibit production of both amyloid precursor protein (APP) and Aβ. We have shown that this inhibition occurs at the post-transcriptional level with a specific blocking of the synthesis of APP relative to total protein synthesis (Shaw et al., 2001). However, the dose of phenserine necessary to block APP production is far higher than that needed to elicit its anticholinesterase activity, and it is these latter actions that are dose limiting in vivo. The focus of this study was to screen 144 analogs of phenserine to identify additional small molecules that inhibit APP protein synthesis, and thereby Aβ production, without possessing potent acetylcholinesterase (AChE) inhibitory activity. An enzyme-linked immunosorbent assay was used to identify analogs capable of suppressing APP production following treatment of human neuroblastoma cells with 20 μM of compound. Eight analogs were capable of dose dependently reducing APP and Aβ production without causing cell toxicity in further studies. Several of these analogs had little to no AChE activities. Translation of APP and Aβ actions to mice was demonstrated with one agent. They thus represent interesting lead molecules for assessment in animal models, to define their tolerance and utility as potential AD therapeutics.",
author = "Tada Utsuki and Yu, {Qian Sheng} and Diane Davidson and Demao Chen and Holloway, {Harold W.} and Arnold Brossi and Kumar Sambamurti and Debomoy Lahiri and Greig, {Nigel H.} and Tony Giordano",
year = "2006",
doi = "10.1124/jpet.106.103309",
language = "English",
volume = "318",
pages = "855--862",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

TY - JOUR

T1 - Identification of novel small molecule inhibitors of amyloid precursor protein synthesis as a route to lower Alzheimer's disease amyloid-β peptide

AU - Utsuki, Tada

AU - Yu, Qian Sheng

AU - Davidson, Diane

AU - Chen, Demao

AU - Holloway, Harold W.

AU - Brossi, Arnold

AU - Sambamurti, Kumar

AU - Lahiri, Debomoy

AU - Greig, Nigel H.

AU - Giordano, Tony

PY - 2006

Y1 - 2006

N2 - A wealth of independent research with transgenic mice, antibodies, and vaccines has pointed to a causative role of the amyloid-β peptide (Aβ) in Alzheimer's disease (AD). Based on these and earlier associative studies, Aβ represents a promising target for development of therapeutics focused on AD disease progression. Interestingly, a cholinesterase inhibitor currently in clinical trials, phenserine, has been shown to inhibit production of both amyloid precursor protein (APP) and Aβ. We have shown that this inhibition occurs at the post-transcriptional level with a specific blocking of the synthesis of APP relative to total protein synthesis (Shaw et al., 2001). However, the dose of phenserine necessary to block APP production is far higher than that needed to elicit its anticholinesterase activity, and it is these latter actions that are dose limiting in vivo. The focus of this study was to screen 144 analogs of phenserine to identify additional small molecules that inhibit APP protein synthesis, and thereby Aβ production, without possessing potent acetylcholinesterase (AChE) inhibitory activity. An enzyme-linked immunosorbent assay was used to identify analogs capable of suppressing APP production following treatment of human neuroblastoma cells with 20 μM of compound. Eight analogs were capable of dose dependently reducing APP and Aβ production without causing cell toxicity in further studies. Several of these analogs had little to no AChE activities. Translation of APP and Aβ actions to mice was demonstrated with one agent. They thus represent interesting lead molecules for assessment in animal models, to define their tolerance and utility as potential AD therapeutics.

AB - A wealth of independent research with transgenic mice, antibodies, and vaccines has pointed to a causative role of the amyloid-β peptide (Aβ) in Alzheimer's disease (AD). Based on these and earlier associative studies, Aβ represents a promising target for development of therapeutics focused on AD disease progression. Interestingly, a cholinesterase inhibitor currently in clinical trials, phenserine, has been shown to inhibit production of both amyloid precursor protein (APP) and Aβ. We have shown that this inhibition occurs at the post-transcriptional level with a specific blocking of the synthesis of APP relative to total protein synthesis (Shaw et al., 2001). However, the dose of phenserine necessary to block APP production is far higher than that needed to elicit its anticholinesterase activity, and it is these latter actions that are dose limiting in vivo. The focus of this study was to screen 144 analogs of phenserine to identify additional small molecules that inhibit APP protein synthesis, and thereby Aβ production, without possessing potent acetylcholinesterase (AChE) inhibitory activity. An enzyme-linked immunosorbent assay was used to identify analogs capable of suppressing APP production following treatment of human neuroblastoma cells with 20 μM of compound. Eight analogs were capable of dose dependently reducing APP and Aβ production without causing cell toxicity in further studies. Several of these analogs had little to no AChE activities. Translation of APP and Aβ actions to mice was demonstrated with one agent. They thus represent interesting lead molecules for assessment in animal models, to define their tolerance and utility as potential AD therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=33745966453&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745966453&partnerID=8YFLogxK

U2 - 10.1124/jpet.106.103309

DO - 10.1124/jpet.106.103309

M3 - Article

VL - 318

SP - 855

EP - 862

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 2

ER -